<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04637165</url>
  </required_header>
  <id_info>
    <org_study_id>R2421</org_study_id>
    <nct_id>NCT04637165</nct_id>
  </id_info>
  <brief_title>Exploring the Immunology of Sarcoidosis</brief_title>
  <official_title>Exploring the Immunology of Sarcoidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hull University Teaching Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of York</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hull University Teaching Hospitals NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In sarcoidosis, over activity of parts of the immune system drives the accumulation of&#xD;
      granulomas (collections of immune cells) in affected parts of the body. To facilitate&#xD;
      development of effective and safe treatment options in the future it will be vital to&#xD;
      understand how and why the immune system becomes over active. The aim of this research is to&#xD;
      work towards this goal by studying cells of the immune system and the molecular pathways&#xD;
      inside these cells that control how they behave. This will be achieved by analysing patterns&#xD;
      of proteins and RNA (the code used to tell cells which proteins to produce) in immune cells&#xD;
      present in blood samples and tissue biopsies from people with sarcoidosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Transcriptomics (RNA) -tissue</measure>
    <time_frame>3 years</time_frame>
    <description>RNA expression and distribution (on different cell types) will be scored quantitatively or semi-quantitatively. Statistical analysis will be descriptive with heat maps for RNA expression (clustered using complete-linkage clustering) and charts (median and interquartile ranges) for comparisons.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Protein - tissue</measure>
    <time_frame>3 years</time_frame>
    <description>Expression and distribution (on different cell types) of proteins which will be scored quantitatively or semi-quantitatively. Results will be descriptive. Comparisons will be made using appropriate statistical techniques.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcriptomics (RNA) - blood</measure>
    <time_frame>3 years</time_frame>
    <description>RNA expression in unstimulated and stimulated blood samples using Nanostring transcriptomics. Statistical analysis will be descriptive with heat maps for RNA and protein expression (clustered using complete-linkage clustering) and charts (median and interquartile ranges) for comparisons.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokines - blood</measure>
    <time_frame>3 years</time_frame>
    <description>Inflammatory mediator concentrations in unstimulated and stimulated blood samples.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Antibodies - blood</measure>
    <time_frame>3 years</time_frame>
    <description>Exploratory description of immunogenic proteins identified by serological analysis of recombinant complementary deoxyribonucleic acid expression libraries.</description>
  </other_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Sarcoidosis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>This is a non-interventional study</intervention_name>
    <description>This is a non-interventional study</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with sarcoidosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females, of any race, between 18 and 85 years of age, inclusive&#xD;
&#xD;
          2. Able to provide written informed consent&#xD;
&#xD;
          3. Clinician diagnosis of sarcoidosis&#xD;
&#xD;
          4. Treatment-na√Øve or receiving immunomodulatory therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Evidence of acute bacterial infection or other condition likely in the opinion of the&#xD;
        investigator to significantly impact results of blood assays.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Simon P Hart, PhD</last_name>
    <phone>+44 1482 624067</phone>
    <email>s.hart@hull.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Castle Hill Hospital</name>
      <address>
        <city>Cottingham</city>
        <state>East Yorkshire</state>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon P Hart, PhD</last_name>
      <phone>+44 1482 624067</phone>
      <email>s.hart@hull.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>macrophage</keyword>
  <keyword>lymphocyte</keyword>
  <keyword>cytokine</keyword>
  <keyword>immunology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

